 |
| TheRNABlog |
mRNA Processing as a System: From Nascent Transcript to Regulatory Network
A systems-biology view of how capping, splicing, 3-prime end formation, export, localization, translation, and decay work together to shape gene expression.
mRNA processing is the set of co- and post-transcriptional
steps that convert nascent transcripts into mature mRNAs (capping, splicing, 3'
cleavage/polyadenylation) and govern mRNA export, localization, translation and
decay. A systems biology perspective treats these steps as an integrated
network regulated by myriad RNA-binding proteins (RBPs) and feedback loops.
High-throughput assays (e.g. RNA-seq, CLIP-seq, NET-seq, long-read and
single-cell RNA-seq, ribosome profiling) have illuminated the genome-wide
architecture and dynamics of this network. Quantitative models (deterministic
ODEs, stochastic simulations, network models) capture aspects like splice-site
selection and noise in gene expression. These approaches reveal how regulatory
circuits and RNA modifications (e.g. m^6A) interconnect processing steps.
Disruptions of mRNA processing underlie developmental programs and diseases
(cancer, neurodegeneration, viral infection) by altering isoforms or global
mRNA flux. We review the scope of mRNA processing, its molecular mechanisms,
regulatory networks, and modeling/data frameworks. Key databases (Ensembl,
ENCODE, GEO) and tools (alignment, CLIP analysis, network inference) are
surveyed. Comparative and evolutionary trends in splicing diversity are
considered (e.g. >60% of plant genes are alternatively spliced). Finally, we
highlight open questions (e.g. integrating spatial/temporal data, modeling
multi-step coupling) and future directions (e.g. single-cell isoform mapping,
machine learning for RBP networks).
Scope and Definitions
The mRNA processing pathway comprises all steps from
transcription to translation that shape an mRNA's sequence, localization, and
lifespan. These include 5' capping, pre-mRNA splicing (removing introns), 3'
end cleavage and polyadenylation, nuclear export, subcellular localization,
translation, and mRNA decay. We focus on eukaryotic mRNAs (no specific organism
assumed), noting that details vary (e.g. yeast has few introns, plants often
use intron retention). In "systems" terms, we view processing not as
isolated reactions but as a network of modules linked by shared factors and
feedback. For example, the "exon junction complex" deposited by
splicing influences both export and surveillance (nonsense-mediated decay).
RNA-binding proteins (RBPs) often act at multiple steps, creating interlocking
regulatory circuits. The processing network is thus hierarchical: transcription
factor cues and chromatin impact splicing, splicing factors regulate export, and
exported mRNAs may in turn regulate transcription factors, etc. This
post-transcriptional regulatory network complements transcriptional networks
and is crucial for cellular homeostasis and response.
Several authoritative resources define these processes. 5'
capping is done by RNA triphosphatase/guanylyltransferase (RTC) during
transcription initiation, enabling subsequent splicing and translation. The
spliceosome (major and minor) removes introns and ligates exons; ~75% of human
genes produce >=2 isoforms. Cleavage/polyadenylation at a poly(A) signal
finishes the transcript and commits it to export. Quality-control pathways
(e.g. the nuclear exosome) degrade aberrant RNAs (e.g. unspliced or with
premature stops). We assume a generic eukaryotic cell by default; when examples
specify, we note the organism (e.g. human ENCODE data or plant studies).
Throughout, we integrate insights from genome-wide studies and database
resources (Ensembl for annotations, ENCODE for RBP binding, GEO for data sets)
to paint a comprehensive picture of the mRNA processing system.
Key Molecular Processes
5' Capping
Immediately after transcription initiation, the nascent
RNA's 5' end is modified: a 7-methylguanosine cap is added by the capping
enzyme complex. This cap protects the RNA and recruits factors for splicing and
export. Systems studies show that co-transcriptional capping is tightly coupled
to RNA Pol II's C-terminal domain (CTD) phosphorylation state. The cap-binding
complex (CBC) remains bound through splicing and export, linking 5' capping to
downstream steps. Defective capping leads to rapid decay.
Splicing
Pre-mRNA splicing is a hierarchical regulatory network
mediated by ~200 proteins (snRNPs, SR/hnRNP proteins) that recognize splice
sites and auxiliary elements. Spliceosomal assembly often occurs
co-transcriptionally (influenced by Pol II speed and chromatin) and is
regulated by combinatorial RBP binding. Global surveys (microarrays and
RNA-seq) reveal pervasiveness: "~75% of human genes encode two or more
splice isoforms". Alternative splicing (AS) creates transcript diversity
by including/excluding exons, and is highly tissue-specific and
signal-responsive. For example, neuronal RBPs like Nova and Rbfox mediate
brain-specific splicing patterns. The "splicing code" - the set of
cis-regulatory motifs and RBPs - has been studied via motif analyses and
perturbations. A useful systems framework includes: (1) cataloging isoforms;
(2) mapping splicing regulatory elements; (3) linking trans-acting RBPs to
target networks; (4) integrating splicing with transcription and mRNP export;
(5) relating splicing changes to signaling and disease. Recent large-scale
studies follow these directions. For instance, systematic knockdown of >300
splicing regulators in human cells revealed specialized splicing networks and
"extensive regulatory potential" of core spliceosome components - in
other words, even core snRNPs have gene-specific regulatory roles. Thus,
splicing is not simply constitutive; it is embedded in feedback loops (e.g.
splicing factors auto-regulate their own pre-mRNAs), and networks of SR
proteins/hnRNPs act akin to gene regulatory networks (see Table 3).
3' Cleavage and Polyadenylation
Termination of transcription is coupled to endonucleolytic
cleavage and poly(A) tail addition. Core factors (CPSF, CstF, PAP) recognize
the AAUAAA motif and downstream elements. Polyadenylation defines the mRNA's 3'
end and influences stability and translation. Alternative polyadenylation (APA)
is widespread: many genes have multiple cleavage sites, yielding mRNAs with
different 3' UTRs or coding sequences. APA can be developmentally regulated and
is influenced by the same RBPs that govern splicing. For example, some SR
proteins and Nova also affect poly(A) site choice. Systems analyses show APA can
alter networks (e.g. by changing miRNA binding sites in 3'UTRs). Viral factors
can disrupt 3' processing: influenza NS1 binds CPSF30 and HSV-1 ICP27 blocks
CPSF assembly, causing genome-wide readthrough transcription and host shut-off.
(Viruses selectively spare their own mRNA processing.)
Nuclear Export
Processed mRNAs are packaged into mRNPs and exported through
the nuclear pore. The NXF1/TAP pathway (often via the TREX complex and exon
junction complex) is the primary route; CRM1/Exportin also handles some
messages. Export is selective: only properly capped, spliced, polyadenylated
RNAs bound by export adaptors can exit. For instance, the exon-junction complex
(EJC) deposited on spliced mRNAs facilitates recruitment of export factors.
Regulatory feedback exists: efficient export can affect Pol II recycling and
gene looping, and conversely, transcription rates influence export kinetics.
High-throughput fractionation studies (nuclear vs cytoplasmic RNA-seq) quantify
export rates genome-wide; transcripts with suboptimal processing are enriched
in the nucleus.
Localization
Once in the cytoplasm, many mRNAs are actively localized via
interactions with transport granules and motor proteins. mRNA localization is
crucial in development (e.g. embryonic axes, neuronal synapses). RBPs that bind
3'UTR "zipcodes" mediate transport; example: the beta-actin mRNA zip
code binds ZBP1 to target cell protrusions. Systems-level data (e.g. spatial
transcriptomics) show clustering of localized mRNAs encoding functionally
related proteins. Localization and local translation form a regulatory loop:
localized mRNA recruits translation machinery in situ, and translationally
repressed granules may store RNAs until signals release them.
Translation Coupling
Translation often begins in the cytoplasm after export. It
is coupled to earlier processing steps via RNP components. For instance,
poly(A) tail length and binding of PABP enhance translation initiation;
conversely, poor splicing can trigger nonsense-mediated decay (NMD) once
translation terminates. The exon junction complex (EJC) left on mRNAs after
splicing licenses proper translation but flags premature stops for NMD. Recent
studies also suggest feedback from translation to RNA fate: stalled ribosomes can
trigger mRNA decay (no-go decay) and influence nuclear events. Ribosome
profiling (Ribo-seq) provides snapshots of translation genome-wide, allowing
direct comparison of transcript and protein production (see High-Throughput
Data below). In summary, the lifecycle of an mRNA is cyclical - its translation
feeds back to decay and indirectly to re-initiation of transcription through
gene looping (in yeast and some metazoans).
Regulatory Networks and Feedback
mRNA processing is governed by networks of RBPs and feedback
loops that integrate cellular signals. RBPs are often multi-functional: large
eCLIP maps show that many RBPs participate in more than one
post-transcriptional process; for example, the Nova protein controls both
alternative splicing and APA. The ENCODE eCLIP project mapped thousands of
RBP-RNA binding sites, enabling the reconstruction of a genome-wide
post-transcriptional regulatory network. They found RBPs connect diverse
processes - splicing, polyadenylation, stability, localization and translation
- into a unified system.
Feedback is built in at multiple levels. Auto-regulation:
Many splicing factors regulate their own transcript splicing to maintain
homeostasis (e.g. SR proteins and hnRNPs often splice-out poison exons in their
own genes). Cross-talk: Splicing can influence transcription: Pol II pausing is
affected by nearby splice signals, and conversely, transcription factors can
recruit splicing factors. RNA surveillance loops: Faulty mRNAs are degraded,
but NMD factors (UPF1/2) can also regulate the expression of splicing
regulators. Signaling integration: Kinase signaling (e.g. SR protein
phosphorylation by SRPK or CLKs) dynamically alters RBP binding, thus globally
reshaping splicing networks in response to external cues.
Systems analyses often use network models to capture these
interactions. For example, transcriptome-wide splicing networks have been
inferred by perturbing RBPs or splicing factors and observing co-splicing
changes. A systematic knockdown study performed systematic knockdowns of 305
spliceosome components, revealing specialized sub-networks for different core
proteins. Similarly, RBP-RNA networks can be modeled as graphs where edges
represent regulation of mRNA stability or translation; computational frameworks
(e.g. Bayesian networks, correlation networks) have been applied to CLIP and
RNA-seq data to predict novel RBP targets. In summary, mRNA processing is
subject to rich regulatory architecture: cellular context and signaling
modulate the components (RBPs, splice sites, polyA signals), which in turn feed
back on mRNA fate. Table 3 lists key RBPs and complexes and their roles.
Quantitative Models of mRNA Dynamics
Mathematical modeling provides insights into mRNA processing
kinetics and noise. Two broad approaches are deterministic vs stochastic
models:
Deterministic (ODE) models assume continuous concentrations
and mass-action kinetics. They are useful for average-case dynamics (e.g.
average splicing rate, mRNA half-life). For instance, one can model
transcription and splicing as sequential first-order reactions. These models
scale well to genome-scale networks but neglect noise.
Stochastic models (Gillespie algorithms) incorporate
discrete molecular events and noise, important when key factors are in low copy
(e.g. a gene transcribed in bursts). Such models can capture cell-to-cell
variability in mRNA levels and alternative isoforms. They often predict
distributions of mRNA counts and can incorporate probabilistic splicing errors.
Kinetic models specifically characterize step-specific
rates. For example, computational kinetic modeling of individual splice sites
(with measured splicing half-lives) has revealed that splicing of long introns
can take minutes, influencing co-transcriptional coupling. Models have also
been used for polyadenylation site choice, where competition between sites is
modeled as a rate process controlled by motif strength and RBP availability.
Network models abstract interactions qualitatively (Boolean
or graph models). For example, RNA-protein interaction networks predict the
effect of perturbing an RBP on downstream mRNA targets. Machine-learning models
(deep learning) now attempt to predict splicing from sequence (SpliceAI) or to
integrate multi-omic data (transcriptome + proteome).
Each modeling approach has trade-offs (Table 1).
Deterministic models are computationally efficient but ignore noise; stochastic
models are realistic but can be intractable for genome-scale. Kinetic models
require many rate constants (often unknown). Logical or network models simplify
complex networks but sacrifice dynamic precision. In practice, hybrids are
used: e.g. deterministic ODEs for abundant components, stochastic for rare
regulators, or coarse-grained network inference supplemented by detailed
kinetics for key modules.
Table 1. Modeling approaches used for mRNA processing
|
Model type |
Assumptions |
Scale/Application |
Strengths |
Limitations |
|
ODE (Deterministic) |
Continuous concentrations, mass-action |
Whole-cell averaged mRNA dynamics |
Simple, analyzable; good for large-scale
modeling of transcript abundance |
Neglects molecular noise; requires parameter
values |
|
Stochastic (Gillespie) |
Discrete events, random timing |
Single-cell/molecule level |
Captures cell-to-cell variability and low-copy
effects |
Computationally intensive for large networks |
|
Kinetic (Compartmental) |
Multi-step reaction rates |
Single-gene or pathway kinetics |
Can incorporate measured rates, good for
detailed kinetics (e.g. splicing time) |
Many parameters; often limited to one or few
genes |
|
Network/Boolean |
Binary states or probabilities; qualitative |
Regulatory network structure |
Identifies key regulators and topology;
integrates multi-omic data |
No temporal dynamics; loses quantitative
detail |
|
Machine Learning |
Data-driven; learns patterns |
Isoform prediction, RBP binding |
Captures complex, nonlinear patterns; uses big
data |
Requires large training sets; interpretability
issues |
High-Throughput Data Types and Analysis
Advances in sequencing and imaging have generated diverse
datasets to probe mRNA processing globally (Table 2). Key technologies include:
Bulk RNA-seq (short reads): Measures transcript abundance
and alternative splicing genome-wide. Typical output: tens to hundreds of
millions of reads (e.g. Illumina). Resolution: exon or junction-level
quantification. Analysis tools include aligners (STAR, HISAT), quantifiers
(Salmon/Kallisto), and splicing tools (rMATS, LeafCutter). RNA-seq reveals gene
expression, isoform ratios, and allelic or condition-specific splicing.
CLIP-seq (e.g. HITS-CLIP, iCLIP, eCLIP): Maps RBP-RNA
interactions in vivo. Crosslinked RNA-protein complexes are immunoprecipitated
and sequenced. Typical output: tens of millions of reads per RBP; resolution
down to ~30nt footprints. Analysis identifies binding sites and motifs.
ENCODE's enhanced CLIP (eCLIP) has catalogued binding for hundreds of RBPs.
NET-seq / GRO-seq: Captures nascent transcripts associated
with active Pol II, mapping transcription and co-transcriptional splicing at
nucleotide resolution. NET-seq (Native Elongating Transcript sequencing)
provides single-nucleotide profiles of elongating Pol II, useful for studying
splicing kinetics and polymerase pausing.
Long-read RNA-seq (PacBio, Oxford Nanopore): Reads >1 kb,
often full-length transcripts. Allows direct observation of complete isoforms,
concatenated splicing and poly(A) choices, and even base modifications (e.g.
m^6A) in single molecules. Nanopore direct RNA sequencing has been used
nanopore direct RNA sequencing to map full-length Arabidopsis mRNAs, revealing
combinatorial diversity of TSS, splicing, poly(A) site, and tail length. Though
lower throughput than short reads, long reads resolve complex isoforms and link
events.
Single-cell RNA-seq (scRNA-seq): Profiles gene expression in
thousands of cells, often with limited isoform resolution. Recent methods aim
to capture isoforms: Smart-seq (full-length) vs 10x Genomics (3' end). Emerging
single-cell isoform sequencing (scISO-seq) uses long reads on single-cell cDNA.
These methods reveal cell-type-specific splicing programs and stochastic
isoform variation.
Ribosome Profiling (Ribo-seq): Sequencing of
ribosome-protected fragments provides codon-resolution maps of translation. It
quantifies translation efficiency of each mRNA and can detect translated
non-canonical ORFs. Comparison of Ribo-seq and RNA-seq yields direct coupling
between transcript levels and protein synthesis.
Each data type has trade-offs (Table 2). For example,
short-read RNA-seq is high-throughput and quantitative but fragments
transcripts; long-read sequencing resolves isoforms but with lower depth and
higher error rate. CLIP requires high quality antibodies and complex analysis.
Table 2. High-throughput data types for mRNA processing
|
Technology |
Resolution |
Throughput |
Typical Outputs |
|
Bulk RNA-seq (Illumina) |
~30–150 bp reads; maps exons/junctions |
High (10^7–10^8 reads/sample) |
Transcript/gene expression; exon/junction
counts; isoform abundance |
|
Single-cell RNA-seq |
Gene-level (3′-bias or full-length) |
10^3–10^5 cells per run |
Gene expression per cell; limited isoform
info; cell clusters and states |
|
Long-read RNA-seq (ONT/PacBio) |
Full-length transcripts (kb) |
Moderate (10^5–10^6 reads) |
Complete isoform sequences; splicing patterns;
poly(A) tails; base modifications |
|
CLIP-seq (HITS/iCLIP/eCLIP) |
~20–50 nt protein footprints |
~10^7 reads per RBP |
RBP binding sites (genome coordinates);
binding motifs; RNA network maps |
|
NET-seq/GRO-seq |
Nucleotide resolution (nascent RNA) |
Moderate |
Pol II occupancy; co-transcriptional splicing
events; pause sites |
|
Ribosome Profiling |
Codon-resolution (~30 nt footprints) |
~10^7 reads/sample |
Ribosome density on mRNAs; translated ORFs;
translation efficiency |
|
Ribo-Zero/PolyA-Seq |
Genome/transcript end maps |
High (10^7 reads) |
Polyadenylation site locations (PolyA-Seq);
non-polyadenylated transcripts (Ribo-Zero RNA-seq) |
In data analysis, computational pipelines integrate these
assays. For example, ENCODE/GEO repositories house thousands of RNA-seq and
CLIP experiments. Bioinformatics tools (e.g. HTSeq, DESeq2 for RNA-seq;
CLIPper, PureCLIP for CLIP) are used to quantify and statistically test
processing differences. Machine learning and network inference tools (e.g.
MEME, RBPmap, SpliceAI) aid motif discovery and splicing prediction. We
recommend Ensembl/GENCODE for transcript annotation, and GEO/ArrayExpress to
access relevant datasets.
Computational Tools and Databases
A multitude of software tools and databases support
systems-level mRNA processing research. Key examples include:
Transcriptome annotation: Ensembl, GENCODE, and RefSeq
curate gene models including splicing isoforms and poly(A) sites. These provide
essential reference transcripts for mapping reads.
Sequence alignment: STAR and HISAT2 are splice-aware RNA-seq
aligners; Salmon and Kallisto perform rapid transcript quantification by
pseudo-alignment. For long reads, minimap2 aligns full-length cDNAs.
Splicing analysis: Tools like rMATS, SUPPA2, and LeafCutter
identify differential splicing from RNA-seq data. The database VAST-DB compiles
alternative splicing in vertebrates and tissues. RBPmap and ATtRACT provide RBP
binding motif annotations.
CLIP analysis: PureCLIP, Paralyzer, and CLIPper call binding
sites from CLIP-seq data. Databases like POSTAR and doRiNA aggregate CLIP
results across RBPs and species.
3'-end processing: TAIL-seq analysis pipelines measure
poly(A) tail lengths; APAlyzer and DaPars detect alternative polyadenylation
from sequencing data. PolyA_DB and APADB catalogs APA sites.
Single-cell tools: STARsolo, CellRanger, and
kallisto|bustools process scRNA-seq. For single-cell splicing, SpliZ and
Velocyto estimate isoform variability.
Databases: The Gene Expression Omnibus (GEO) and EMBL-EBI
ArrayExpress archive raw RNA-seq and CLIP-seq datasets. ENCODE and modENCODE
portals provide richly annotated RBP binding and expression data.
Domain-specific DBs include RBPDB (RNA-binding protein database) and doRiNA
(database of RBP targets).
For network analysis, frameworks like WGCNA (for
co-expression) and Graphia (for gene networks) can integrate multi-omic layers.
Tools such as Cytoscape visualize RBP-RNA networks. Emerging platforms (e.g.
EnrichRBP) automate integrative analysis of RBP function. Collectively, these
computational resources enable reconstruction and interrogation of mRNA
processing systems from diverse data.
Cross-Species and Evolutionary Perspectives
mRNA processing exhibits both conserved machinery and
species-specific innovations. All eukaryotes perform capping, splicing,
polyadenylation and export, but genome architectures differ markedly. Simple
eukaryotes (yeasts) have few introns and limited alternative splicing, whereas
multicellular eukaryotes show extensive AS. For instance, over 60% of
Arabidopsis intron-containing genes are alternatively spliced, reflecting
complex gene regulation in plants. Mammals and insects also have high AS rates;
the Drosophila Dscam gene famously can produce thousands of isoforms. In
contrast, yeast introns are rare and mostly constitutive.
Comparative genomics reveals that the core processing
factors (snRNP proteins, CPSF, export factors) are broadly conserved, implying
an early origin. However, the regulatory layers have expanded in complex
organisms. Many RBPs present in vertebrates have no yeast homologs.
Cross-species CLIP studies show some splicing regulators have conserved targets
(e.g. SR proteins bind purine-rich motifs in animals and plants), but the bulk
of AS patterns diverge with species. Evolutionary analyses indicate that many
tissue-specific splice events are rapidly evolving, while core housekeeping
splicing is conserved.
Polyadenylation signals (AAUAAA) are nearly universal in
metazoans, though plants use A-rich variants. The coupling between splicing and
3' end processing is ancient: even plants show coordination. mRNA localization
signals and RBPs (like zipcode-binding proteins) vary by lineage - for example,
vertebrate neurons rely on different zip codes than yeast, which has simpler
transport needs.
These differences have functional consequences. Alternative
splicing and APA have been proposed to contribute to species diversity without
increasing gene number. In development, organisms exploit these mechanisms
differently: e.g. vertebrate embryogenesis involves extensive AS changes, while
in Arabidopsis stress responses trigger specific splice variants. Systems
studies often compare transcriptomes across species to identify
lineage-specific regulatory networks. Future work in comparative
epitranscriptomics (e.g. mapping m^6A across species) will further illuminate
evolutionary trajectories of mRNA processing.
Roles in Development and Disease
Proper mRNA processing is essential for normal development
and physiology. During development, regulated AS and APA create protein
isoforms tailored to cell types. Examples include neuron-specific isoforms of
neurotransmitter receptors and developmental stage shifts in 3'UTR length
(longer UTRs in early embryogenesis, shorter in differentiating cells). RBPs
like CELF, PTBP, and Hu proteins show developmental regulation, ensuring
stage-specific splicing patterns.
Cancer: Many cancers exhibit mis-splicing and APA changes.
Mutations in splicing factor genes are common in myeloid leukemias (e.g. SF3B1,
U2AF1) and seen in solid tumors (TCGA analyses). Aberrant splicing can activate
oncogenes or inactivate tumor suppressors. For instance, intron retention or
exon skipping in apoptosis regulators can promote survival. APA shifts in
cancer often truncate 3'UTRs, escaping miRNA repression and increasing oncogene
translation. Large surveys (e.g. Kahles et al. 2018) show pan-cancer splicing
signatures and RBP expression changes linked to tumor type. Targeting splicing
(splice-switching oligonucleotides or SF3B inhibitors) is an emerging
therapeutic strategy.
Neurodegeneration: Neurons heavily depend on mRNA
processing. Mutations in RBPs (TDP-43, FUS, hnRNPA1) cause ALS/FTD; these proteins
normally regulate neuronal splicing and RNA transport. Tau exon 10 mis-splicing
underlies frontotemporal dementia. Widespread splicing dysregulation is
observed in Alzheimer's and Parkinson's brains. mRNA localization is also
critical in neurons - defects in localizing synaptic mRNAs can impair
connectivity and learning.
Developmental and other disorders: Defects in core
processing factors cause congenital diseases. For example, mutations in the
U4atac snRNA (minor spliceosome) cause microcephalic osteodysplastic primordial
dwarfism. Poly(A) signal mutations (e.g. FOXP3 AAUAAA→AUAAAG) lead to
immunodeficiency. In viral infection, host mRNA processing is actively
disrupted: as discussed above, viral proteins block cleavage/polyadenylation or
even accelerate host mRNA decay to evade immunity. Some viruses rely on
alternative splicing (e.g. HIV's multiple proteins from one transcript) or use
unique poly(A) strategies (adenovirus uses very short poly(A) tails).
Single-gene disorders: Many monogenic diseases involve
splicing errors (e.g. cystic fibrosis DeltaF508 creates an aberrant splice
site; spinal muscular atrophy is due to SMN2 exon 7 skipping). Clinically,
antisense therapies that redirect splicing (e.g. Spinraza for SMA) demonstrate
the power of targeting this system.
Experimental and Modeling Gaps, Open Questions
Despite advances, significant gaps remain in our
systems-level understanding. Integration across scales is incomplete: we lack
unified models linking transcription dynamics to cytoplasmic translation
outcomes. For example, how exactly does transcriptional bursting propagate to
splicing noise and then to protein levels? Spatial context is underexplored:
live-cell imaging (e.g. MS2 tagging of mRNA) shows granule assembly and
transport, but genome-wide integration of spatial data (MERFISH or seqFISH of
isoforms) is in its infancy. Single-cell complexity: while scRNA-seq profiles
expression, single-cell isoform sequencing (long-read or linked reads) is just
emerging. How heterogeneous is splicing within a "cell type"?
Existing single-cell datasets often miss isoform-level detail, creating an
analysis gap.
On the regulatory side, functional relevance of RBP binding
sites is not fully known. CLIP maps hundreds of thousands of sites, but most
lack characterized function. We need perturbation screens (e.g. saturating
mutagenesis of UTRs) to link binding to outcome. Feedback mechanisms (e.g. how
poly(A) tail length influences nuclear fate) need more quantitative data.
Additionally, post-transcriptional modifications (m^6A, m^5C) are known to
affect processing and stability, but the global networks of "writers,
readers, erasers" in context of processing are still being mapped.
Modeling-wise, parameterization is a bottleneck. Many
kinetic models assume constant rates, but in vivo rates vary by context. Direct
kinetic measurements (e.g. metabolic labeling and nascent RNA-seq) provide some
data, but integrating these into genome-scale models is challenging. Complex
feedback loops pose theoretical challenges: for example, coupling of
transcription termination with splicing through Pol II requires multi-scale
simulation (chromatin, polymerase, RNP assembly) that current models cannot
fully capture.
Finally, data biases and noise are issues. Short-read
RNA-seq can misassign isoforms, and CLIP has false positives. Standardizing experimental
protocols (e.g. benchmarks in CLIP-seq) and integrating replicates is ongoing.
In summary, we need better data integration frameworks, more direct
measurements of processing kinetics, and novel assays (e.g. simultaneous
long-read sequencing of DNA, RNA, and proteins in single cells).
Future Directions and Recommendations
Looking ahead, multimodal single-cell technologies promise
to revolutionize the field. Techniques combining long-read sequencing with
single-cell resolution, or linking epigenetic state to transcript isoforms,
will reveal cell-type-specific RNA processing landscapes. For example,
single-cell nanopore RNA-seq is emerging. Integrating spatial transcriptomics
(e.g. FISSEQ, MERFISH) with isoform resolution will map processing in tissue
context, crucial for development studies.
Machine learning and data integration will grow in
importance. Deep learning models (like SpliceAI) are already predicting
splicing from sequence; expanding these to multi-step processing predictions
(incorporating motifs, RBP expression, modifications) is a goal. Network
inference algorithms that combine CLIP, expression, and phenotype data (e.g.
CRISPR screens of RBPs) can build more accurate regulatory maps.
Experimentally, CRISPR-based screens targeting RBP binding
sites or splice sites at scale will clarify functional networks. RNA-structure
methods such as DMS-MaPseq and Nano-DMS-MaP and enhanced CLIP variants will
improve our view of RNA secondary structure in vivo, informing processing
mechanisms.
Finally, therapeutic targeting of the mRNA processing
machinery is a growing frontier. Engineered RBPs and small molecules that
modulate splicing, including SF3B-targeting compounds such as H3B-8800, have
reached clinical testing. Understanding mRNA processing networks at systems
level will better predict off-target effects of such interventions.
Table 3. Key RNA-processing regulators
|
Factor/Complex |
Role in mRNA
Processing |
|
Capping enzymes
(RNGTT, RNMT) |
Add and methylate 5′ cap; recruit cap-binding
proteins. |
|
Spliceosome snRNPs
(U1, U2, U4/U6, U5 complexes) |
Core machinery for intron removal. Recognizes
splice sites. |
|
SR proteins
(SRSF1-12) |
SR-rich splicing factors; promote exon
recognition and alternative splicing. |
|
hnRNP proteins
(hnRNP A/B, C, D, etc.) |
Splicing repressors, often compete with SR
proteins to regulate splice choice. |
|
Polyadenylation factors (CPSF subunits, CstF, CFIm) |
Recognize poly(A) signals; cleave pre-mRNA and
recruit poly(A) polymerase. |
|
Poly(A) polymerase (PAP) |
Catalyzes poly(A) tail addition. |
|
Poly(A) binding proteins (PABPN1, PABPC) |
Bind poly(A) tails; regulate translation and
tail length. |
|
Nuclear export factors (NXF1/TAP, REF/Aly) |
Mediate mRNP export through nuclear pore.
Coupled to splicing via the TREX complex. |
|
RNA decay enzymes
(DCP2/DCP1 decapping, XRN1 exonuclease, exosome complex) |
Remove cap or degrade from ends; perform
quality control and mRNA turnover. |
|
Regulatory RBPs
(ELAVL/Hu proteins, FMRP, TIA1) |
Bind specific sequences (e.g. AU-rich or
G-quartets) to modulate stability, localization or translation. |
|
Nonsense-mediated decay (NMD) factors (UPF1, SMG1) |
Trigger decay of aberrant transcripts with
premature stop codons; links to splicing (EJC-dependent). |
|
|
|
Suggested figure: a lifecycle flowchart showing co-transcriptional capping, splicing, and polyadenylation in the nucleus; export through the nuclear pore; and cytoplasmic localization, translation, and decay, with RBPs and m6A marks acting across multiple stages.
Selected References
Core mechanisms and reviews
Rules of engagement: co-transcriptional recruitment of
pre-mRNA processing factors. Current Opinion in Cell Biology, 2005.
https://pubmed.ncbi.nlm.nih.gov/15901493/
Global analysis of mRNA splicing. RNA, 2008.
https://pubmed.ncbi.nlm.nih.gov/18083834/
Transcriptional termination in mammals: Stopping the RNA
polymerase II juggernaut. Science, 2016.
https://doi.org/10.1126/science.aad9926
Modulation of mRNA 3-prime-End Processing and Transcription
Termination in Virus-Infected Cells. Frontiers in Immunology, 2022.
https://www.frontiersin.org/articles/10.3389/fimmu.2022.828665/full
Complexity of the Alternative Splicing Landscape in Plants.
The Plant Cell, 2013. https://academic.oup.com/plcell/article/25/10/3657/6099545
Nanopore direct RNA sequencing maps the complexity of
Arabidopsis mRNA processing and m6A modification. eLife, 2020.
https://elifesciences.org/articles/49658
RBP networks and high-throughput assays
Principles of RNA processing from analysis of enhanced CLIP
maps for 150 RNA binding proteins. Nature, 2020.
https://pubmed.ncbi.nlm.nih.gov/32252787/
CLIP and complementary methods. Nature Reviews Methods
Primers, 2021. https://doi.org/10.1038/s43586-021-00018-1
Transcriptome-wide splicing network reveals specialized
regulatory functions of the core spliceosome. Science, 2024.
https://pubmed.ncbi.nlm.nih.gov/39480945/
eCLIP Data Standards. ENCODE Project, accessed 2026.
https://www.encodeproject.org/eclip/
Nano-DMS-MaP allows isoform-specific RNA structure
determination. Nature Methods, 2023.
https://www.nature.com/articles/s41592-023-01862-7
Modeling, tools, and databases
Stochastic gene expression and its consequences. Cell, 2008.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3118044/
Predicting Splicing from Primary Sequence with Deep
Learning. Cell, 2019. https://doi.org/10.1016/j.cell.2018.12.015
EnrichRBP: an automated and interpretable computational
platform for predicting and analysing RNA-binding protein events.
Bioinformatics, 2025.
https://academic.oup.com/bioinformatics/article/41/1/btaf018/7953276
GENCODE: The GENCODE Project. GENCODE, accessed 2026.
https://www.gencodegenes.org/pages/gencode.html
Ensembl annotation. Ensembl, accessed 2026. https://grch37.ensembl.org/info/genome/genebuild/index.html
Gene Expression Omnibus. NCBI, accessed 2026.
https://www.ncbi.nlm.nih.gov/geo/
Disease and therapeutic context
Comprehensive Analysis of Alternative Splicing Across Tumors
from 8,705 Patients. Cancer Cell, 2018.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9844097/
Phase I First-in-Human Dose Escalation Study of the oral
SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia, 2021.
https://www.nature.com/articles/s41375-021-01328-9
FDA approves first drug for spinal muscular atrophy. U.S.
FDA, 2016.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-spinal-muscular-atrophy
Nusinersen, an antisense oligonucleotide drug for spinal
muscular atrophy. Nature Neuroscience, 2017. https://www.nature.com/articles/nn.4508
